Frederick Ueland is a graduate of Stanford University and received his medical degree from the Wake Forest University, School of Medicine, Winston-Salem, N.C. He then completed a fellowship in Gynecologic Oncology at the University of Kentucky, Lexington. He is board certified by the American Board of Obstetrics and Gynecology in Gynecologic Oncology.

Dr. Ueland's special interests include ovarian tumor evaluation with ultrasound and biomarkers, treatment of ovarian cancer, and advanced pelvic surgery. He is an active translational researcher at the NCI-designated Markey Cancer Center, and was the principal investigator for the OVA-1 trial which resulted in FDA-clearance for the ovarian tumor blood test in 2009. He is also the Medical Director of Gynecologic Surgery, and Medical Director of Outpatient Chemotherapy and Infusion for UK HealthCare. He serves on a number of local and national cancer committees.

Faculty Rank